Management ChangeMay 6, 2026, 04:37 PM
Bionano Genomics Appoints Albert Luderer Interim CEO
AI Summary
Bionano Genomics, Inc. announced a leadership transition, with R. Erik Holmlin, Ph.D. terminated as President and Chief Executive Officer, effective May 5, 2026. Dr. Holmlin also resigned from the Board of Directors. Albert A. Luderer, Ph.D., the current Chairman, has been appointed Interim Chief Executive Officer and interim principal financial officer. The company will initiate a search for a permanent CEO, and Christopher J. Twomey was appointed Lead Independent Director.
Key Highlights
- R. Erik Holmlin, Ph.D. was terminated as President and CEO, effective May 5, 2026.
- Dr. Holmlin resigned from the Company's Board of Directors and any committees.
- Albert A. Luderer, Ph.D. appointed Interim Chief Executive Officer and interim principal financial officer.
- Dr. Luderer will continue as Chairman but no longer serve on the Compensation, Audit, and Nominating Committees.
- Christopher J. Twomey appointed Lead Independent Director and a member of the Compensation Committee.
- Dr. Luderer's annual base salary is $600,000.
- Dr. Luderer's 2026 annualized incentive bonus opportunity is up to $400,000.
- Dr. Luderer will receive a housing and travel stipend of $4,000 per month.
- The Company intends to promptly commence a search for a permanent Chief Executive Officer.